AbstractObjective To evaluate the impact of sarcopenia on survival and treatment‐related toxicity in postoperative recurrent esophageal squamous cell carcinoma (ESCC) patients treated with chemoradiotherapy. Methods Clinical data of 147 patients with postoperative locoregional recurrent ESCC receiving chemoradiotherapy in Huai'an First People's Hospital from 2016 to 2017 were retrospectively analyzed. Pectoralis muscle area (PMA) was determined using routine pre‐radiotherapy CT simulation scan above the aortic arch level. Sarcopenia was defined as a cut‐off value of pectoralis muscle index (PMI) (PMA/height2) <11.55 cm2/m2 for males and <8.69 cm2/m2 for females. The incidence of toxicity, 1‐ and 3‐year overall survival (OS) rates were statistically compared between patients with and without sarcopenia. Results Sarcopenia was detected in 49 of 147 (33.3%) patients. The incidence of grade 3‐4 toxicities in sarcopenic patients was significantly higher compared to that in their counterparts without sarcopenia (40.8% vs. 18.4%,P=0.005). In addition, patients with sarcopenia had significantly worse 1‐year (61.2% vs. 82.7%) and 3‐year OS rates (10.2% vs. 28.6%) than those without sarcopenia (both , P<0.001). Multivariate analysis showed that sarcopenia was an independent prognostic factor for poor OS (P<0.001). Conclusion PMI based on CT simulation scan has prognostic value in postoperative locoregional recurrent ESCC patients treated with chemoradiotherapy, which probably serves as a novel diagnostic tool for sarcopenia.
Zhou Xilei,Yu Changhua,Zhu Weiguo et al. Effect of sarcopenia on survival and toxicity in postoperative recurrent esophageal squamous cell carcinoma patients receiving chemoradiotherapy[J]. Chinese Journal of Radiation Oncology, 2022, 31(9): 785-790.
Zhou Xilei,Yu Changhua,Zhu Weiguo et al. Effect of sarcopenia on survival and toxicity in postoperative recurrent esophageal squamous cell carcinoma patients receiving chemoradiotherapy[J]. Chinese Journal of Radiation Oncology, 2022, 31(9): 785-790.
[1] Chen J, Yin W, Yao H, et al.Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma[J]. Radiat Oncol, 2019, 14(1):169. DOI: 10.1186/s13014‐019‐1377‐y. [2] 沈文斌, 许金蕊, 李曙光, 等. 食管癌术后复发患者放化疗疗效及预后分析[J]. 中华放射医学与防护杂志, 2021, (9): DOI: 10.3760/cma.j.issn.0254‐5098.2021.09.007. Shen WB, Xu JR, Li SG, et al.Analyses of therapeutic effects and prognosis of patients with postoperative recurrent esophageal cancer[J].Chin J Radiol Med Protect,2021,(9)DOI: 10.3760/cma.j.issn.0254‐5098.2021.09.007. [3] 张金野, 陈林敏, 陈永东. 肌肉减少症对食管癌术后并发症影响的Meta分析[J]. 现代肿瘤医学, 2018, 26(3): 382‐387. DOI: 10.3969/j.issn.1672‐4992.2018.03.015. Zhang JY, Chen LM, Chen YD.A Meta‐analysis of postoperative complications related to preoperative sarcopenia in patients with esophageal cancer[J].J Modern Oncol,2018,26(3):382‐387. DOI: 10.3969/j.issn.1672‐4992.2018.03.015. [4] 中国抗癌协会肿瘤营养与支持治疗专业委员.肌肉减少症营养治疗指南[J].肿瘤代谢与营养电子杂志, 2015, 2(3):32‐36. DOI:10.16689/j.cnki.cn11‐9349/r.2015.03.003. Chinese Society for Oncological Nutrition & Supportive Care. Nutritional treatment guidelines for sarcopenia[J]. Electron J Metab Nutr Cancer, 2015, 2(3):32‐36. DOI: 10.16689/j.cnki.cn11‐9349/r.2015.03.003. [5] 王璐, 陈永春, 谢晓冬. 恶性肿瘤患者肌肉减少症的诊断与营养干预[J]. 中华临床营养杂志, 2013, 21(1): 23‐29. DOI: 10.3760/cma.j.issn.1674‐635X.2013.01.006. Wang L, Chen YC, Xie XD. Caring sarcopenia for cancer patients: review[J].Chin J Clin Nutrit,2013,21(1):23‐29. DOI: 10.3760/cma.j.issn.1674‐635X.2013.01.006. [6] Kinsey CM, San José Estépar R, van der Velden J, et al. Lower pectoralis muscle area is associated with a worse overall survival in non‐small cell lung cancer[J]. Cancer Epidemiol Biomarkers Prev, 2017, 26(1):38‐43. DOI: 10.1158/1055‐9965.EPI‐15‐1067. [7] McDonald ML, Diaz AA, Ross JC, et al. Quantitative computed tomography measures of pectoralis muscle area and disease severity in chronic obstructive pulmonary disease. A cross‐sectional study[J]. Ann Am Thorac Soc, 2014, 11(3):326‐334. DOI: 10.1513/AnnalsATS.201307‐229OC. [8] Ufuk F, Demirci M, Sagtas E, et al.The prognostic value of pneumonia severity score and pectoralis muscle area on chest CT in adult COVID‐19 patients[J]. Eur J Radiol, 2020, 131:109271. DOI: 10.1016/j.ejrad.2020.109271. [9] Sun C, Anraku M, Kawahara T, et al. Prognostic significance of low pectoralis muscle mass on preoperative chest computed tomography in localized non‐small cell lung cancer after curative‐intent surgery[J]. Lung Cancer, 2020, 147:71‐76. DOI: 10.1016/j.lungcan.2020.07.008. [10] Sanders K, Degens J, Dingemans AC, et al. Cross‐sectional and longitudinal assessment of muscle from regular chest computed tomography scans: L1 and pectoralis muscle compared to L3 as reference in non‐small cell lung cancer[J]. Int J Chron Obstruct Pulmon Dis, 2019, 14:781‐789. DOI: 10.2147/COPD.S194003. [11] Elliott JA, Doyle SL, Murphy CF, et al. Sarcopenia: prevalence,impact on operative and oncologic outcomes in the multimodal management of locally advanced esophageal cancer[J]. Ann Surg, 2017, 266(5):822‐830. DOI: 10.1097/SLA.0000000000002398. [12] Lee J, Chang CL, Lin JB, et al. Skeletal muscle loss is an imaging biomarker of outcome after definitive chemoradiotherapy for locally advanced cervical cancer[J]. Clin Cancer Res, 2018, 24(20):5028‐5036. DOI: 10.1158/1078‐0432.CCR‐18‐0788. [13] Nipp RD, Fuchs G, El‐Jawahri A, et al. Sarcopenia is associated with quality of life and depression in patients with advanced cancer [J]. Oncologist, 2017, 23:97‐104. DOI: 10.1634/theoncologist.2017‐0255. [14] Zwart AT, van der Hoorn A, van Ooijen P, et al. CT‐measured skeletal muscle mass used to assess frailty in patients with head and neck cancer[J]. J Cachexia Sarcopenia Muscle, 2019, 10(5):1060‐1069. DOI: 10.1002/jcsm.12443. [15] Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment[J]. Clin Cancer Res, 2009, 15(8):2920‐2926. DOI: 10.1158/1078‐0432.CCR‐08‐2242. [16] Panje CM, Höng L, Hayoz S, et al.Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: a SAKK 75/08 substudy[J]. Radiat Oncol, 2019, 14(1):166. DOI: 10.1186/s13014‐019‐1372‐3. [17] Hua X, Liao JF, Huang X, et al.Sarcopenia is associated with higher toxicity and poor prognosis of nasopharyngeal carcinoma[J]. Ther Adv Med Oncol, 2020, 12:1758835920947612. DOI: 10.1177/1758835920947612. [18] Kurita Y, Kobayashi N, Tokuhisa M, et al. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy[J]. Pancreatology, 2019, 19(1):127‐135. DOI: 10.1016/j.pan.2018.11.001. [19] Iritani S, Imai K, Takai K, et al. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma[J]. J Gastroenterol, 2015, 50(3):323‐332. DOI: 10.1007/s00535‐014‐0964‐9. [20] Feliciano EMC, Kroenke CH, Meyerhardt JA, et al.Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCANS study[J]. JAMA Oncol, 2017, 3:e172319. DOI: 10.1001/jamaoncol. 2017.2319. [21] Srpcic M, Jordan T, Popuri K, et al. Sarcopenia and myosteatosis at presentation adversely affect survival after esophagectomy for esophageal cancer[J]. Radiol Oncol, 2020, 54(2):237‐246. DOI: 10.2478/raon‐2020‐0016. [22] Sato S, Kunisaki C, Suematsu H, et al. Impact of sarcopenia in patients with unresectable locally advanced esophageal cancer receiving chemoradiotherapy[J]. In Vivo, 2018, 32(3):603‐610. DOI: 10.21873/invivo.11282. [23] Onishi S, Tajika M, Tanaka T, et al. Prognostic significance of sarcopenia in patients with unresectable advanced esophageal cancer[J]. J Clin Med, 2019, 8(10)DOI: 10.3390/jcm8101647. [24] Nakashima Y, Saeki H, Nakanishi R, et al. Assessment of sarcopenia as a predictor of poor outcomes after esophagectomy in elderly patients with esophageal cancer[J]. Ann Surg, 2018, 267(6):1100‐1104. DOI: 10.1097/SLA.0000000000002252.
2022, Vol. 31 
